Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Operations: 2019-2024

Historic Cash from Operations for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$194.5 million.

  • Kymera Therapeutics' Cash from Operations rose 45.99% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.9 million, marking a year-over-year decrease of 82.82%. This contributed to the annual value of -$194.5 million for FY2024, which is 89.16% down from last year.
  • Per Kymera Therapeutics' latest filing, its Cash from Operations stood at -$194.5 million for FY2024, which was down 89.16% from -$102.8 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Cash from Operations peaked at $88.1 million during FY2020, and registered a low of -$194.5 million during FY2024.
  • Its 3-year average for Cash from Operations is -$150.1 million, with a median of -$153.1 million in 2022.
  • Per our database at Business Quant, Kymera Therapeutics' Cash from Operations spiked by 392.21% in 2020 and then tumbled by 246.31% in 2021.
  • Over the past 5 years, Kymera Therapeutics' Cash from Operations (Yearly) stood at $88.1 million in 2020, then slumped by 246.31% to -$128.9 million in 2021, then fell by 18.72% to -$153.1 million in 2022, then surged by 32.83% to -$102.8 million in 2023, then slumped by 89.16% to -$194.5 million in 2024.